Discontinue in case of persisting severe diarrhoea; severe nausea & vomiting symptoms; if any liver test elevations are associated w/ clinical signs or symptoms of liver injury eg, jaundice; GI perforation develops. Diarrhoea & vomiting leading to dehydration w/ or w/o electrolyte disturbances. Increased risk of bleeding & thromboembolic events. Nephrotic syndrome. Patients w/ recent history of MI or stroke; higher CV risk including known CAD; previous abdominal surgery, recent history of hollow organ perforation, previous history of peptic ulceration, diverticular disease. Low body wt (<65 kg), Asian, female & Black patients. Monitor for hepatic transaminase & bilirubin levels upon initiation of treatment at regular intervals during 1st 3 mth of treatment & periodically thereafter. Concomitant use w/ corticosteroids or NSAIDs. May affect ability to drive & use machines. Not recommended in patients w/ moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Severe renal impairment (CrCl <30 mL/min). Women of childbearing potential should avoid becoming pregnant during treatment & use highly effective contraceptive methods at initiation, during & at least 3 mth after last dose. Women taking oral hormonal contraceptives experiencing vomiting & diarrhea should use alternative highly effective contraceptive measure. Not to be applied during pregnancy. Lactation. Childn & adolescents. Reduce dose to manage adverse effects in elderly ≥75 yr.